Quantcast

Latest OSI Pharmaceuticals Stories

2008-09-08 09:00:52

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the appointment of Nicholas Bacopoulos, Ph.D., to its Board of Directors. Dr. Bacopoulos has more than 25 years of experience at leading biotechnology and pharmaceutical companies, serving in multiple executive positions and managing the discovery and development of novel anticancer agents. "Nicholas Bacopoulos is a valuable addition to Cyclacel's board of directors bringing extensive knowledge and understanding of...

2008-09-04 12:00:07

Osi Pharmaceuticals has started a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the company is developing for the treatment of type 2 diabetes. Discovered by Osi's diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies. PSN821 is said to be the third development candidate discovered in-house that the company has moved into clinical development...

2008-09-03 09:00:08

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated a first-in-human clinical study for its G-protein coupled receptor GPR119 agonist, PSN821, which the Company is developing for the treatment of type 2 diabetes. Discovered by OSI's diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies. Pre-clinical data on PSN821 was the subject of an oral presentation at this year's...

2008-07-16 12:00:20

OSI Pharmaceuticals has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the Torc1 and Torc2 complexes that inhibits the kinase activity associated with mTOR. The study is designed to determine the maximum tolerated dose and to establish the recommended dose and dosing schedule for Phase II trials, and will evaluate the safety and pharmacokinetic profiles of OSI-027. The Phase I trial is a multi-center, open-label, dose escalation study to...

2008-07-15 09:00:16

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it has initiated a Phase I clinical trial of OSI-027, an oral, potent and selective inhibitor of both the TORC1 and TORC2 complexes that inhibits the kinase activity associated with mTOR (mammalian target of rapamycin). The study is designed to determine the maximum tolerated dose (MTD) and to establish the recommended dose and dosing schedule for Phase II trials, and will evaluate the safety and pharmacokinetic profiles of...

2008-06-20 12:00:07

Osi Pharmaceuticals has initiated the first-in-human clinical study of its development compound PSN602, an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity. The double-blind, placebo-controlled, ascending, single and multiple, oral dose study is designed to provide preliminary information on the safety, tolerability and pharmacokinetics of PSN602 in healthy lean and obese subjects, as well as on the effects of PSN602...

2008-06-20 00:00:06

OSI Pharmaceuticals, Inc. (Investors/Media) Kathy Galante, 631-962-2043 or (Media) Kim Wittig, 631-962-2135 or Burns McClellan (Representing OSI) Justin Jackson/Kathy Nugent (Media) 212-213-0006 Logo: http://www.osip.com OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated the first-in-human clinical study of its development compound PSN602. Discovered by OSI's diabetes and obesity team, PSN602 is an oral dual serotonin and norepinephrine...

2008-06-19 09:00:08

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has initiated the first-in-human clinical study of its development compound PSN602. Discovered by OSI's diabetes and obesity team, PSN602 is an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity. PSN602 is the first clinical candidate to emerge from the Company's research efforts in obesity. "Our research efforts are focused on designing innovative,...

2006-08-29 08:24:22

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...

2006-08-29 05:04:54

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related